HPV vaccination for HIV carriers

Vitaly B. Kaliberdenko , Alexander A. Gorlov , Elvina R. Kulieva , Kulanthaivel Shanmugaraj , Victoria S. Beter , Emiliya R. Zagidullina , Tatiana S. Pronkina , Nadezhda K. Plaksina

For citation:

Abstract

Goal. to form a point of view on the expediency, amount of doses, and vaccination schemes for HIV carriers by analyzing scientific articles. Materials and methods. the literature review includes an analysis of scientific papers from the databases PubMed, MEDLINE, Embase, eLibrary, CyberLeninka and GoogleScholars, using the search terms "HIV", "HPV", "vaccination".

Results. Carriers of HIV infection, even when receiving antiretroviral therapy, have an increased risk of contracting the human papillomavirus, and progression to malignant complications occurs much faster. Important factors are: CD4 levels in the body, viral load, vaccination schedule, and the presence of concomitant gynecological diseases. A mixed vaccination schedule with an initial dose of Cervarix is one of the priorities that promotes more active antibody production; such schemes are safe and effective.

Conclusion. For successful antibody production, a low number of viral particles is required, and alternative vaccination schedules are required to maintain high antibody titers. Combinations of several HPV vaccines and mandatory hepatitis B vaccination contribute to a better immune response. The Cervarix vaccine was more active in producing antibodies than the Gardasil vaccine. This issue remains more relevant than ever for HIV-carriers.

Keywords: HPV vaccination, immune response, HIV transmission, antibody production, vaccination regimen.

References

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30.

2. Информационный бюллетень 2023 г. Глобальная статистика по ВИЧ. URL: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_ru.pdf Fact Sheet 2023. Global HIV Statistics. URL: https://www.unaids.org/ sites/default/files/media_asset/UNAIDS_FactSheet_ru.pdf (in Russian).

3. Wilkin TJ, Chen H, Cespedes MS et al. Randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 Years or older: AIDS clinical trials group protocol A5298. Clin Infect Dis 2018;67:1339-46. DOI: 10.1093/cid/ciy274

4. Cespedes MS, Kang M, Kojic E.M et al. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1. Papillomavirus Res 2018;6:15-21. DOI: 10.1016/j.pvr.2018.08.002

5. Wei F, Gaisa MM, D'Souza G et al. Epidemiology of anal infection caused by human papillomavirus and high-grade squamous cell intraepithelial lesions in 29,900 men, depending on HIV status, sexual orientation and age: a joint analysis of 64 studies. Lancet HIV 2021;8:e531-e543. DOI: 10.1016/S2352-3018(21)00108-9

6. Giuliano AR, Isaacs-Soriano K, Torres BN et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27–45 years)-The MAM Study. Vaccine 2015;33:5640-6. DOI: 10.1016/j.vaccine.2015.08.072

7. Faust H, Toft L, Sehr P et al. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine 2016;4:1559-65. DOI: 10.1016/j.vaccine.2016.02.019

8. Trimble CL, Morrow MP, Kraynyak KA et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 2015;386:2078.

9. Drolet M, Bénard É, Pérez N et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019;394:497.

10. Giacomet V, Penagini F, Trabattoni D et al. Safety and immunogenicity of a quadrivalent vaccine against human papillomavirus in HIV-infected and HIV-negative adolescents and young adults. Vaccine 2014;32:5657–61. DOI: 10.1016/j.vaccine.2014.08.011

11. Cubas R, van Grevenynghe J, Wills S et al. Reversible reprogramming of circulating memory T follicular helper cell function during chronic HIV infection. J Immunol 2015;195:5625-36. DOI: 10.4049/ jimmunol.1501524 12. Cohen C, von Mollendorf C, de Gouveia L. et al. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in South Africa: a matched case-control study. Clin Infect Dis 2014;59:808-18. DOI: 10.1093/cid/ciu431

13. Pinto LA, Kemp TJ, Torres BN et al. Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. J Infect Dis 2016;214:1276–83. DOI: 10.1093/infdis/jiw359

14. Combe J-D, Hurd I, Poiseau-Martin I et al. Prevalence and risk factors of anal infection caused by human papillomavirus in men who have sex with men infected with human immunodeficiency virus. J Infect Dis 2018;217:1535-43. DOI: 10.1093/infdis/jiy059

15. Bogale AL, Belai NB, Medin G, Ali JH. Molecular epidemiology of human papillomavirus among HIV-infected women in developing countries: a systematic review and meta-analysis. Virol J 2020;17:179. DOI: 10.1186/s12985-020-01448-1

16. McClymont E, Lee M, Raboud Jet al. The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with HIV. Clin Infect Dis 2019;68:788-94. DOI: 10.1093/cid/ciy575

17. Moscicki AB, Karalius B, Tassiopoulos Ket al. Human papillomavirus antibody levels & quadrivalent vaccine clinical effectiveness in perinatally. Human Immunodeficiency Virus-infected and exposed, uninfected youth. Clin Infect Dis 2019. DOI:10.1093/cid/ciy1040

18. Denny L, Hendricks B, Gordon C et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine 2013;31:5745-53. DOI: 10.1016/j.vaccine.2013.09.032

19. Giuliano AR, Palefsky JM, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364:401-11. DOI: 10.1056/NEJMoa0909537

20. Weinberg A, Huang S, Moscicki AB et al. IMPAACT P1085 Protocol Team. Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children. AIDS 2018;32:851-9. DOI: 10.1097/QAD.0000000000001773

21. Wilkin TJ, Chen H, Cespedes MS et al. A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 Years or older: AIDS clinical trials group protocol A5298. Clin Infect Dis 2018;67:1339-46. DOI: 10.1093/cid/ciy274

22. Weinberg A, Song LY, Saah A et al. Humoral, mucosal, and cell-mediated immunity against vaccine and non-vaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis 2012;206:1309-18. DOI: 10.1093/infdis/jis489

23. Ellsworth GB, Lensing SY, Ogilvie CB et al. A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men. Papillomavirus Res 2018;6:11-14. DOI: 10.1016/j.vaccine.2016.02.019

24. Wilkin TJ, Chen H, Cespedes MS et al. A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 Years or older: AIDS clinical trials group protocol A5298. Clin Infect Dis 2018;67:1339-46. DOI: 10.1093/cid/ciy575

25. Folschweiler N, Teixeira J, Joshi S et al. End of Study Results of a 2 Year Multicountry Phase IV Randomized Comparative Study of the Immunogenicity and Safety of the AS04-HPV-16/18 Vaccine and the HPV-6/11/16/18 Vaccine in HIV-Positive Female Subjects Aged 15–25 Years. EUROGIN Lisbon 2018. Abstract 275.

26. Einstein MH, Levin MJ, Chatterjee Aet al. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: follow-up through month 48 in a phase III randomized study. Hum Vaccines Immunother 2014;10(12):3455-65. DOI: 10.4161/hv.36117

27. Moscicki AB, Karalius B, Tassiopoulos K et al. Human papillomavirus antibody levels & quadrivalent vaccine clinical effectiveness in perinatally Human Immunodeficiency Virus-infected and exposed, uninfected youth. Clin Infect Dis 2019. DOI: 10.1093/cid/ciy1040

28. Cooper CL, Angel JB, Seguin I et al. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term sero-protection for up to 5 years. Clin Infect Dis 2008;46:1310-4. DOI: 10.1086/533467

29. Szarewski A, Skinner SR, Garland S et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low risk HPV types (PATRICIA randomised trial): an unexpected observation. Journal of Infectious Diseases 2013;208(9):1391-6. DOI: 10.1093/infdis/jit360

30. Howell-Jones R, Soldan K, Wetten S et al. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J Infect Dis 2013;208:1397-403. DOI: 10.1093/infdis/jit361

31. Nyagol J, Leucci E, Onnis A et al. The effect of HIV-1 Tat protein on the cell cycle during cervical carcinogenesis. Biology of cancer. Therapy 2006;5:684-90. DOI: 10.4161/cbt.5.6.2907.43

32. Kim RH, Joachim JM, Kang M.K et al. HIV-1 Tat enhances the replicative potential of human oral keratinocytes containing the HPV-16. Int J Oncol 2008;33:777-82.

33. Gladikova K, Kutski V, Bucek Y et al. Tumor-infiltrating B cells influence the progression of squamous cell carcinoma of the oropharynx through intercellular interactions with CD8+ T cells. J ImmunoTherapy Cancer 2019;7:1-16. DOI: 10.1186/s404

34. Wu I, Meng L, Cai K et al. A gene signature based on CD8+ T cells infiltrating the tumor for predicting and evaluating the immune response in squamous cell carcinoma of the head and neck caused by HPV. Front Oncology 2021;11:1-12. DOI: 10.3389/fonc.2021.749398.47

35. Beachler DC, Abraham AG, Silverberg MJ et al. Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oncol 2014;50:1169. DOI: 10.1016/j.oraloncology.2014.09.011

36. Clifford GM, Georges D, Shiels MS et al. Meta-analysis of the incidence of colorectal cancer depending on the risk group: towards a unified risk scale for rectal cancer. Int J Cancer 2021;148:38-47. DOI: 10.1002/ijc.33185

37. Brophy J, Bitnun A, Alimenti A et al. Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV. Pediatr Infect Dis J 2018;37:595-7. DOI: 10.1097/INF. 0000000000001874 38. Kemp TJ, Garcia-Pineres A, Falk RT et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008;26:3608-16. DOI: 10.1016/j.vaccine.2008.04.074

39. Dauner JG, Pan Y, Hildesheim A et al. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 2010;28:5407-13. DOI: 10.1016/j.vaccine.2010.06.018

40. Guiguet M, Boue F, Cadranel J et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009;10:1152-9. DOI: 10.1016/S1470-2045(09)70282-7

41. Money DM, Moses E, Blitz S et al. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. Vaccine 2016;34:4799–806. DOI: 10.1016/j.vaccine.2016.08.016

42. Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS 1994;8:558-9. DOI: 10.1097/00002030-199404000-00024

43. Parmigiani A, Alcaide ML, Freguja R et al. Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation. PLoS One 2013;8:e79816. DOI: 10.1371/journal.pone.0079816

44. Joura EA, Kjaer SK, Wheeler CM et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008;26:6844-51. DOI: 10.1016/j.vaccine. 2008.09.073

45. Bachmann MF, Kalinke U, Althage A et al. The role of antibody concentration and avidity in antiviral protection. Science 1997;276:2024-7. DOI: 10.1126/science.276.5321.2024

46. Delmas MC, Larsen C, van Benthem B et al. Cervical squamous intraepithelial lesions in HIV-infected women: prevalence, incidence and regression. European Study Group on Natural History of HIV Infection in Women. AIDS 2000;14:1775-84. DOI: 10.1097/00002030-200008180-00013

47. Dauner JG, Pan Y, Hildesheim A, Kemp TJ et al. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes 2012;26:73-80. DOI: 10.1016/j.mcp.2012.01.002

48. Herrin DM, Coates EE, Costner PJ et al. Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. Hum Vaccin Immunother 2014;10:3446-54. DOI: 10.4161/hv.34408

49. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 2012;10:681-92. DOI: 10.1038/nrmicro2872

50. Kojic EM, Kang M, Cespedes MS et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis 2014;59:127-35. DOI: 10.1093/cid/ciu238

51. Kahn JA, Xu J, Kapogiannis BG et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis 2013;57:735-44. DOI: 10.1093/cid/cit319

For citation:Kaliberdenko V.B., Gorlov A.A., Kulieva E.R., Kulanthaivel Sh., Beter V.S., Zagidullina E.R., Pronkina T.S., Plaksina N.K. HPV vaccination for HIV carriers. Clinical review for general practice. 2025; 6 (9): 125–129 (In Russ.). DOI: 10.47407/kr2025.6.9.00685

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice